Asset Details
Do you wish to reserve the book?
Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
Do you wish to request the book?
Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
2022
Overview
Immune checkpoint inhibitors are associated with a spectrum of cutaneous immune-related adverse events. While maculopapular eruptions are the most common cutaneous adverse event, scleroderma can rarely develop. Herein, we report a case of new-onset scleroderma associated with avelumab treatment in the setting of metastatic squamous cell carcinoma of the lung. The pathophysiology of immune checkpoint inhibitor-induced scleroderma is not completely understood. A proposed mechanism is discussed along with the clinical presentation of symptoms and associated therapeutic response in cancer treatment. This case contributes to the few existing reports of immune checkpoint inhibitor-induced scleroderma to better understand the implications in the management of cutaneous immune-related adverse events.
Publisher
Hindawi,John Wiley & Sons, Inc,Wiley
Subject
